HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pol Specenier Selected Research

BI 6727

11/2019Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.
1/2019In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
10/2015A phase I study of volasertib combined with afatinib, in advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pol Specenier Research Topics

Disease

20Neoplasms (Cancer)
10/2021 - 12/2011
18Squamous Cell Carcinoma of Head and Neck
10/2021 - 05/2007
15Head and Neck Neoplasms (Head and Neck Cancer)
04/2021 - 05/2007
7Melanoma (Melanoma, Malignant)
02/2021 - 12/2012
4Glioblastoma (Glioblastoma Multiforme)
05/2017 - 01/2012
3Deglutition Disorders (Dysphagia)
03/2020 - 09/2015
3Mucositis
11/2017 - 05/2007
2Oropharyngeal Neoplasms
04/2021 - 06/2016
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2019 - 01/2019
2Febrile Neutropenia
06/2016 - 03/2010
2Disease Progression
04/2015 - 12/2012
2Colorectal Neoplasms (Colorectal Cancer)
04/2015 - 01/2010
1Malnutrition (Nutritional Deficiencies)
01/2021
1Lymphatic Metastasis
01/2021
1Lung Neoplasms (Lung Cancer)
01/2021
1Hypoxia (Hypoxemia)
01/2019
1Xerostomia
08/2018
1Diabetes Mellitus
01/2018
1Uveal melanoma
01/2018
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2018
1Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
01/2018
1Ketosis
01/2018
1Pain (Aches)
11/2017
1Squamous Cell Neoplasms (Squamous Cell Cancer)
12/2016
1Anorexia
06/2016
1Exanthema (Rash)
06/2016
1Diarrhea
06/2016
1Tonsillar Neoplasms
06/2016
1Glioma (Gliomas)
01/2012
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
04/2011

Drug/Important Bio-Agent (IBA)

8NivolumabIBA
04/2021 - 08/2016
8Cetuximab (Erbitux)FDA Link
01/2018 - 05/2007
6PlatinumIBA
01/2021 - 04/2011
6Biomarkers (Surrogate Marker)IBA
01/2020 - 01/2010
6ErbB Receptors (EGF Receptor)IBA
12/2016 - 01/2010
5pembrolizumabIBA
04/2021 - 08/2016
5IpilimumabIBA
02/2021 - 12/2012
5Fluorouracil (Carac)FDA LinkGeneric
01/2018 - 05/2007
4Monoclonal AntibodiesIBA
02/2021 - 01/2017
4Phosphotransferases (Kinase)IBA
05/2020 - 10/2015
4Cisplatin (Platino)FDA LinkGeneric
01/2018 - 05/2007
3LigandsIBA
10/2021 - 01/2015
3Immune Checkpoint InhibitorsIBA
04/2021 - 01/2018
3BI 6727IBA
11/2019 - 10/2015
3Paclitaxel (Taxol)FDA LinkGeneric
04/2019 - 12/2016
3Docetaxel (Taxotere)FDA Link
01/2018 - 10/2011
3Bevacizumab (Avastin)FDA Link
01/2016 - 01/2012
2Pharmaceutical PreparationsIBA
02/2021 - 11/2019
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
05/2020 - 01/2017
2Dacarbazine (DIC)FDA LinkGeneric
05/2020 - 04/2019
2Polo-Like Kinase 1IBA
11/2019 - 01/2019
2Methotrexate (Mexate)FDA LinkGeneric
01/2018 - 06/2016
2Transforming Growth Factors (Transforming Growth Factor)IBA
05/2017 - 01/2016
2LY-2157299IBA
05/2017 - 01/2016
2Lomustine (CCNU)FDA Link
05/2017 - 01/2016
2AfatinibIBA
06/2016 - 10/2015
2taxaneIBA
06/2016 - 05/2007
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2015 - 01/2012
1monalizumabIBA
10/2021
1HLA Antigens (Human Leukocyte Antigens)IBA
10/2021
1tipifarnib (R115777)IBA
10/2021
1avelumabIBA
04/2021
1durvalumabIBA
04/2021
1Epidermal Growth Factor (EGF)IBA
01/2021
1binimetinibIBA
05/2020
1130-nm albumin-bound paclitaxelIBA
04/2019
1Therapeutic UsesIBA
01/2019
1BariumIBA
08/2018
1Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA
01/2018
1islet cell antibodyIBA
01/2018
1Immunoglobulin G (IgG)IBA
01/2018
1Glial Fibrillary Acidic ProteinIBA
05/2017
1Chemokine CCL22IBA
05/2017
1Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
05/2017
1Death Domain ReceptorsIBA
01/2017
1Carboplatin (JM8)FDA LinkGeneric
12/2016
1MEHD7945AIBA
12/2016
1AntibodiesIBA
08/2016
1GemcitabineFDA Link
01/2016
1Transcription Factors (Transcription Factor)IBA
01/2015
1Heparin-binding EGF-like Growth Factor (HB-EGF)IBA
01/2015
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
01/2015
1ApigeninIBA
11/2014
1Proteins (Proteins, Gene)FDA Link
11/2014
12- ((3- ((4- ((5- (2- ((3- fluorophenyl)amino)- 2- oxoethyl)- 1H- pyrazol- 3- yl)amino)quinazolin- 7- yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphateIBA
11/2014
1DNA (Deoxyribonucleic Acid)IBA
06/2014
1Ciprofloxacin (Cipro)FDA LinkGeneric
03/2010
1Hyaluronic Acid (Hyaluronan)IBA
01/2010
1Biological ProductsIBA
01/2010

Therapy/Procedure

12Therapeutics
01/2020 - 05/2007
9Drug Therapy (Chemotherapy)
04/2021 - 04/2015
5Radiotherapy
03/2020 - 04/2011
4Immunotherapy
04/2021 - 08/2016
4Chemoradiotherapy
04/2021 - 09/2015
2Induction Chemotherapy
02/2015 - 02/2014
1Activities of Daily Living (ADL)
01/2021
1Combination Drug Therapy (Combination Chemotherapy)
01/2018
1Continuity of Patient Care
04/2015
1Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
03/2015
1Biological Therapy
01/2012